Notification That Annual Report Will Be Submitted Late (nt 10-k)
03 Aprile 2023 - 3:13PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 12b-25
NOTIFICATION OF LATE FILING |
OMB APPROVAL |
OMB Number: 3235-0058 |
Expires: April 30, 2025 |
Estimated average burden hours per response ... 2.50 |
|
SEC FILE NUMBER |
001-37353 |
|
CUSIP NUMBER |
|
(Check
one): |
|
☒
Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D
☐ Form N-SAR ☐ Form N-CSR |
|
|
|
|
|
For Period Ended: |
December
31, 2022 |
|
|
|
|
|
☐
Transition Report on Form 10-K |
|
|
|
|
|
☐
Transition Report on Form 20-F |
|
|
|
|
|
☐
Transition Report on Form 11-K |
|
|
|
|
|
☐
Transition Report on Form 10-Q |
|
|
|
|
|
☐
Transition Report on Form N-SAR |
|
|
|
|
|
For
the Transition Period Ended: |
Read
Instruction (on back page) Before Preparing Form. Please Print or Type.
Nothing in this form shall be construed
to imply that the Commission has verified any information contained herein.
|
If the notification relates
to a portion of the filing checked above, identify the Item(s) to which the notification relates:
PART I — REGISTRANT
INFORMATION
BiondVax Pharmaceuticals Ltd. |
Full Name of Registrant |
|
Former Name if Applicable |
Jerusalem BioPark, 2nd Floor, Hadassah Ein Kerem Campus |
Address of Principal Executive Office (Street and Number) |
Jerusalem, Israel |
City, State and Zip Code |
PART II — RULES 12b-25(b)
AND (c)
If the subject report could not be filed without unreasonable effort
or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)
☒ |
(a) |
The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense; |
|
|
(b) |
The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report of transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof will be filed on or before the fifth calendar day following the prescribed due date; and |
|
|
(c) |
The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable. |
PART III — NARRATIVE
State below in reasonable detail the reasons why
Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed
time period.
BIONDVAX PHARMACEUTICALS LTD. (the “Registrant”)
was unable, without unreasonable effort or expense, to file its Annual Report on Form 10-K for the year ended December 31, 2022, due to
a delay experienced by the Registrant in completing its financial statements and other disclosures in the Annual Report. This delay is
due to this being the first Form 10-K and first set of financial statements being prepared in accordance with U.S. GAAP instead of International
Financial Reporting Standards that the Company has been required to prepare. As a result, the Registrant is still in the process of compiling
required information to complete the Annual Report. The Registrant anticipates that it will file the Annual Report no later than
April 17, 2023 (the first business day after the fifteenth calendar day following the prescribed filing date).
PART IV — OTHER INFORMATION
| (1) | Name and telephone number of
person to contact in regard to this notification |
Uri Ben-Or |
|
+972 |
|
8-930-2529 |
(Name) |
|
(Area Code) |
|
(Telephone Number) |
(2) |
Have all other
periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment
Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such
report(s) been filed? If answer is no, identify report(s). |
|
Yes ☒ No ☐ |
|
|
(3) |
Is it anticipated that
any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings
statements to be included in the subject report or portion thereof? |
|
Yes ☒ No ☐ |
|
|
|
If
so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons
why a reasonable estimate of the results cannot be made.
The
Registrant anticipates a significant decrease in net loss from the corresponding period for the last fiscal year to be reflected
by the earnings statements to be included in the Annual Report, including due to (i) an increase in research and development expenses,
(ii) a decrease in marketing, general and administrative expenses, and (iii) a increase in net financial income |
BIONDVAX PHARMACEUTICALS LTD.
(Name of Registrant as Specified in Charter)
has caused this notification to be signed on its
behalf by the undersigned hereunto duly authorized.
April 3, 2023 |
By: |
/s/ Uri Ben-Or |
|
Name: |
Uri Ben-Or |
|
Title: |
Chief Financial Officer |
3
Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Mag 2024 a Giu 2024
Grafico Azioni BiondVax Pharmaceuticals (NASDAQ:BVXV)
Storico
Da Giu 2023 a Giu 2024